Infection News

In these videos, Jessica R. Allegretti, MD, MPH, medical director of the Crohn's and Colitis Center at the Brigham and Women's Hospital discusses the latest treatments, preventative options, and unmet needs for patients with Clostridioides difficile infection.

In these videos, Jessica R. Allegretti, MD, MPH, medical director of the Crohn's and Colitis Center at the Brigham and Women's Hospital discusses the latest treatments, preventative options, and unmet needs for patients with Clostridioides difficile infection.

In these videos, Jessica R. Allegretti, MD, MPH, medical director of the Crohn's and Colitis Center at the Brigham and Women's Hospital discusses the latest treatments, preventative options, and unmet needs for patients with Clostridioides difficile infection.

In these videos, Jessica R. Allegretti, MD, MPH, medical director of the Crohn's and Colitis Center at the Brigham and Women's Hospital discusses the latest treatments, preventative options, and unmet needs for patients with Clostridioides difficile infection.

In these videos, Jessica R. Allegretti, MD, MPH, medical director of the Crohn's and Colitis Center at the Brigham and Women's Hospital discusses the latest treatments, preventative options, and unmet needs for patients with Clostridioides difficile infection.

In these videos, Jessica R. Allegretti, MD, MPH, medical director of the Crohn's and Colitis Center at the Brigham and Women's Hospital discusses the latest treatments, preventative options, and unmet needs for patients with Clostridioides difficile infection.

In these videos, Jessica R. Allegretti, MD, MPH, medical director of the Crohn's and Colitis Center at the Brigham and Women's Hospital discusses the latest treatments, preventative options, and unmet needs for patients with Clostridioides difficile infection.

Researchers in Spain reported that nearly half of supermarket meat samples tested in a study contained multidrug-resistant or potentially pathogenic Escherichia coli.

The FDA has approved Vowst, the first orally administered fecal microbiota product indicated for the prevention of recurrent Clostridioides difficile infection in adults following antibacterial treatment.

A novel oral microbiome-directed therapy called VE303 successfully prevented recurrent Clostridioides difficile infection in adults at high risk for recurrence, researchers found.